Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

1.
2.
4.

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.

Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR, Piccart M, Delorenzi M.

Breast Cancer Res. 2008;10(4):R65. doi: 10.1186/bcr2124. Epub 2008 Jul 28.

5.

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas.

Kuo WH, Chang YY, Lai LC, Tsai MH, Hsiao CK, Chang KJ, Chuang EY.

PLoS One. 2012;7(9):e45831. doi: 10.1371/journal.pone.0045831. Epub 2012 Sep 25.

6.

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.

Lehmann BD, Ding Y, Viox DJ, Jiang M, Zheng Y, Liao W, Chen X, Xiang W, Yi Y.

BMC Cancer. 2015 Mar 26;15:179. doi: 10.1186/s12885-015-1102-7.

7.

Bayesian meta-analysis models for microarray data: a comparative study.

Conlon EM, Song JJ, Liu A.

BMC Bioinformatics. 2007 Mar 7;8:80.

8.

Prognostic value of a 92-probe signature in breast cancer.

Akter S, Choi TG, Nguyen MN, Matondo A, Kim JH, Jo YH, Jo A, Shahid M, Jun DY, Yoo JY, Nguyen NN, Seo SW, Ali L, Lee JS, Yoon KS, Choe W, Kang I, Ha J, Kim J, Kim SS.

Oncotarget. 2015 Jun 20;6(17):15662-80.

9.

Merging microarray data from separate breast cancer studies provides a robust prognostic test.

Xu L, Tan AC, Winslow RL, Geman D.

BMC Bioinformatics. 2008 Feb 27;9:125. doi: 10.1186/1471-2105-9-125.

10.

Mixture classification model based on clinical markers for breast cancer prognosis.

Zeng T, Liu J.

Artif Intell Med. 2010 Feb-Mar;48(2-3):129-37. doi: 10.1016/j.artmed.2009.07.008. Epub 2009 Dec 14.

PMID:
20005686
11.

Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.

Sørlie T, Wang Y, Xiao C, Johnsen H, Naume B, Samaha RR, Børresen-Dale AL.

BMC Genomics. 2006 May 26;7:127.

12.

Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor.

De Cecco L, Bossi P, Locati L, Canevari S, Licitra L.

Ann Oncol. 2014 Aug;25(8):1628-35. doi: 10.1093/annonc/mdu173. Epub 2014 May 14.

PMID:
24827125
13.

Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer.

Lin YH, Friederichs J, Black MA, Mages J, Rosenberg R, Guilford PJ, Phillips V, Thompson-Fawcett M, Kasabov N, Toro T, Merrie AE, van Rij A, Yoon HS, McCall JL, Siewert JR, Holzmann B, Reeve AE.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):498-507.

14.
15.

Clinical relevance of DNA microarray analyses using archival formalin-fixed paraffin-embedded breast cancer specimens.

Sadi AM, Wang DY, Youngson BJ, Miller N, Boerner S, Done SJ, Leong WL.

BMC Cancer. 2011 Jun 16;11:253:1-13. doi: 10.1186/1471-2407-11-25.

16.

Combining gene signatures improves prediction of breast cancer survival.

Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale AL, Lingjærde OC.

PLoS One. 2011 Mar 10;6(3):e17845. doi: 10.1371/journal.pone.0017845.

17.

Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer.

Karlsson E, Delle U, Danielsson A, Olsson B, Abel F, Karlsson P, Helou K.

BMC Cancer. 2008 Sep 8;8:254. doi: 10.1186/1471-2407-8-254.

18.

Effects of sample size on robustness and prediction accuracy of a prognostic gene signature.

Kim SY.

BMC Bioinformatics. 2009 May 16;10:147. doi: 10.1186/1471-2105-10-147.

19.

Maximizing biomarker discovery by minimizing gene signatures.

Chang C, Wang J, Zhao C, Fostel J, Tong W, Bushel PR, Deng Y, Pusztai L, Symmans WF, Shi T.

BMC Genomics. 2011 Dec 23;12 Suppl 5:S6. doi: 10.1186/1471-2164-12-S5-S6. Epub 2011 Dec 23.

20.

A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients.

Molloy TJ, Roepman P, Naume B, van't Veer LJ.

PLoS One. 2012;7(2):e32426. doi: 10.1371/journal.pone.0032426. Epub 2012 Feb 23.

Supplemental Content

Support Center